Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

Benzinga Newsdesk www.benzinga.com Negative 88.8%

Neg 88.8% Neu 0% Pos 0%

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.